I agree that this site is using cookies. You can find further informations here.
X
Schreck, Karisa
66  results:
Search for persons X
?
1

BIOM-43. LOSS OF NF1 PROTEIN EXPRESSION IS A POOR PROGNOSTI..:

Chang, Michael ; Chinnasamy, Viveka ; Ioannou, Maria...
Neuro-Oncology.  25 (2023)  Supplement_5 - p. v14-v14 , 2023
Link: https://doi.org/10.1093/..
 
?
2

Management and Molecular Characterization of Intraventricul..:

Parker, Megan ; Kalluri, Anita ; Materi, Joshua...
International Journal of Molecular Sciences.  24 (2023)  17 - p. 13285 , 2023
Link: https://doi.org/10.3390/..
 
?
3

BIMG-23. SINGLE-VOXEL VERSUS MULTI-SLICE MRSI IN PATIENTS W..:

Munjapara, Vasu ; Kamson, David ; Berrington, Adam...
Neuro-Oncology Advances.  3 (2021)  Supplement_1 - p. i6-i6 , 2021
Link: https://doi.org/10.1093/..
 
?
4

DDRE-31. FEASIBILITY AND BIOLOGIC ACTIVITY OF A KETOGENIC /..:

Schreck, Karisa ; Hsu, Fang-Chi ; Berrington, Adam...
Neuro-Oncology Advances.  3 (2021)  Supplement_1 - p. i13-i13 , 2021
Link: https://doi.org/10.1093/..
 
?
5

DDRE-13. DECONVOLUTING MECHANISMS OF RESISTANCE TO BRAF INH..:

Schreck, Karisa ; Morin, Andrew ; Zhao, Guisheng...
Neuro-Oncology.  22 (2020)  Supplement_2 - p. ii64-ii64 , 2020
Link: https://doi.org/10.1093/..
 
?
6

PATH-26. INTEGRATED MOLECULAR AND CLINICAL ANALYSIS OF BRAF..:

Schreck, Karisa ; Langat, Pinky ; Li, Taibo.
Neuro-Oncology.  22 (2020)  Supplement_2 - p. ii169-ii170 , 2020
Link: https://doi.org/10.1093/..
 
?
7

ACTR-44. FEASIBILITY, PHARMACODYNAMICS, AND BIOLOGIC ACTIVI..:

Schreck, Karisa ; Hsu, Fang-Chi ; Berrington, Adam...
Neuro-Oncology.  21 (2019)  Supplement_6 - p. vi23-vi23 , 2019
Link: https://doi.org/10.1093/..
 
?
8

Incidence and Natural History of H3 K27M-mutated Midline Gl..:

Schreck, Karisa ; Ranjan, Surabhi ; Skorupan, Nebojsa..
Neurology.  92 (2019)  15_supplement - p. , 2019
Link: https://doi.org/10.1212/..
 
?
9

EXTH-39. BENCH TO BEDSIDE NEURO-ONCOLOGY: ADVOCATING FOR A ..:

Zammar, Samer ; Madden, Dennis ; Schreck, Karisa...
Neuro-Oncology.  21 (2019)  Supplement_6 - p. vi90-vi90 , 2019
Link: https://doi.org/10.1093/..
 
?
10

Combined Pharmacologic Inhibition of MEK-ERK and PI3K/mTOR ..:

Schreck, Karisa ; Allen, Amy ; Wang, Jiawen.
Neurology.  92 (2019)  15_supplement - p. , 2019
Link: https://doi.org/10.1212/..
 
?
11

PATH-28. THE NATURAL HISTORY OF BRAF V600E-MUTATED GLIOBLAS..:

Schreck, Karisa ; Vera, Elizabeth ; Aboud, Orwa...
Neuro-Oncology.  20 (2018)  suppl_6 - p. vi164-vi164 , 2018
Link: https://doi.org/10.1093/..
 
?
12

Assessing cerebral metabolic activity of an Atkins-based di..:

Schreck, Karisa ; Berrington, Adam ; Henry-Barron, Bobbie...
Neurology.  90 (2018)  15_supplement - p. , 2018
Link: https://doi.org/10.1212/..
 
?
13

PATH-35. FREQUENCY AND CHARACTERISTICS OF H3K27M-MUTATION I..:

Schreck, Karisa ; Ranjan, Surabhi ; Skorupan, Nebojsa..
Neuro-Oncology.  20 (2018)  suppl_6 - p. vi166-vi166 , 2018
Link: https://doi.org/10.1093/..
 
?
14

Cyclopamine-Mediated Hedgehog Pathway Inhibition Depletes S..:

Bar, Eli E. ; Chaudhry, Aneeka ; Lin, Alex...
Stem Cells.  25 (2007)  10 - p. 2524-2533 , 2007
Link: https://doi.org/10.1634/..
 
?
15

No drug holidays in BRAFV600E glioma patients: An argument ..:

Bazer, Danielle A ; Kolchinski, Anna ; Bush, Nancy A O...
Neuro-Oncology Practice.  , 2024
Link: https://doi.org/10.1093/..
 
1-15